- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Retrospective Study of Alternate-day Administration of Gefitinib
-
- Fujita Takuya
- Department of Thoracic Surgery, Shiga University of Medical Science
-
- Teramoto Koji
- Department of Thoracic Surgery, Shiga University of Medical Science
-
- Ozaki Yoshitomo
- Department of Thoracic Surgery, Shiga University of Medical Science
-
- Tezuka Noriaki
- Department of Thoracic Surgery, Shiga University of Medical Science
-
- Sawai Satoru
- Department of Thoracic Surgery, Shiga University of Medical Science
-
- Fujita Minako
- Department of Thoracic Surgery, Shiga University of Medical Science
-
- Fujino Shozo
- Department of Thoracic Surgery, Shiga University of Medical Science
Bibliographic Information
- Other Title
-
- ゲフィチニブ隔日投与症例の検討
Search this article
Description
Objective. To perform a retrospective investigation of alternate-day administration of gefitinib for reduction of side effects and to determine the efficacy of this approach for maintenance therapy. Methods. We gave gefitinib to 50 patients from July 2002 to May 2004. All patients were initially treated with 250 mg gefitinib daily, and with long-term administration 12 patients developed mild side effects. Administration of gefitinib was reduced to alternate days in these patients, and here we report the effects of this dosage in the 12 patients. Results. All patients showed a reduction of adverse events and long-term gefitinib administration became possible again. The average time to treatment failure (TTF) was 18.4 months for daily administration and 10.9 months for alternate-day administration. However, efficacy of the drug has been maintained for over 600 days in 4 women. Conclusion. Alternate-day administration of gefitinib is useful for reduction of adverse reactions and can serve as an effective maintenance therapy; however, a further prospective study is needed for comparison with other administration schedules.<br>
Journal
-
- Haigan
-
Haigan 47 (1), 9-12, 2007
The Japan Lung Cancer Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679659527168
-
- NII Article ID
- 110006242067
-
- NII Book ID
- AN00203978
-
- ISSN
- 13489992
- 03869628
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed